LACRYSTIM™: CE mark approval

CLERMONT-FERRAND, France - May 29, 2019 - Quantel Medical today announced the CE mark approval of LacryStim™ IPL system. Based on intense pulsed light technology, LacryStim™ is used for the treatment of dry eye diseases such as Meibomian gland dysfunction.

Dry eye disease is a multifactorial disease of the tears and ocular surface that can result in ocular discomfort and visual impairment. It affects all populations across the world with a major increase in people over 50 years old and is expected to increase as the population continues to age. LacryStim™ IPL is a treatment device featuring a unique wavelengths spectrum and train of pulses enabling the stimulation of the lachrymal and Meibomian glands and the reduction of inflammation. These mechanisms of action help the improvement of the tear film quality and the reduction of the major symptoms associated with mild to moderate dry eye diseases.

“LacryStim™ IPL system is the second product of our dry eye range and brings an innovative therapeutic solution to ophthalmologists confronted to the daily challenge of dry eye treatment. It complements ideally with LacryDiag™, our dry eye diagnostic platform launched in 2018.” said Jean-Marc Gendre, CEO of Quantel Medical. “With the release in 2017 of the DEWS 2 report setting new standards of diagnosis and treatment, Quantel Medical is proud to bring a complete diagnosis and treatment solution that meets with the requirements of the new standards of care in dry eye diseases.”

Ophthalmologists attending the congresses of the French Society of Ophthalmology in Paris, France this month and the European Society of Ophthalmology, Nice, France in June will have the opportunity to discover LacryStim™.
About Quantel Medical

Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the diagnosis and treatment of ocular diseases. Quantel Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions and a comprehensive product portfolio of diagnostic ultrasound, surgical lasers and a range of disposable products for ophthalmologists. These products are available through direct sales operations in the U.S., France and Poland, and through 80 independent distributors in over 110 countries. Quantel Medical is a division of Lumibird (LBIRD - FR0000038242 / Paris), a world-wide leader in the development of solid state lasers for scientific and industrial applications.

www.quantel-medical.com

Company contact:
Jan-Philippe Heydel: Jan-Philippe.Heydel@quantel-medical.fr

Media contact:
Stephanie Belot Stephanie.Belot@quantel-medical.fr